HPV-mediated PARP1 regulation and drug sensitization in head and neck cancer
Our study demonstrates that PARP1 is upregulated in HPV-positive HN tumours and cell lines, compared to HPV-negative. Despite the higher sensitivity of HPV-positive HNC cell lines to olaparib and cisplatin compared to HPV-negative cells, the combination of cisplatin with olaparib synergistically inhibits cell viability across all HNC cell lines tested, regardless of HPV status. This combination may allow for reduced drug concentrations, potentially decreasing side effects and enhancing therapeutic efficacy in HN tumours.
Authors
- Simona Citro (ORCID: https://orcid.org/0000-0003-3561-1824)
- Claudia Miccolo (ORCID: https://orcid.org/0000-0001-8823-7843)
- Mohssen Ansarin (ORCID: https://orcid.org/0000-0002-8384-5388)
- Marta Tagliabue (ORCID: https://orcid.org/0000-0002-7879-4846)
- Mirko Doni (ORCID: https://orcid.org/0000-0001-7099-2701)
- Susanna Chiocca (ORCID: https://orcid.org/0000-0002-9721-0850)
- Lavinia Ghiani (ORCID: https://orcid.org/0000-0001-6298-0495)
Institutions
- European Institute of Oncology (IT)
Publication Details
- Journal
- Oral Oncology
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1016/j.oraloncology.2025.107307
- Citations
- 4
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- Ministero della Salute
- Fondazione Umberto Veronesi
- Associazione Italiana per la Ricerca sul Cancro
- Fondazione per la Ricerca Biomedica
- Regione Lombardia